Sanofi (SNYNF)
USD 98.65
(0.0%)
USD 98.65
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 52.11 Billion EUR | 2.03% |
| 2022 | 51.07 Billion EUR | -0.27% |
| 2021 | 51.21 Billion EUR | -0.33% |
| 2020 | 51.38 Billion EUR | -4.19% |
| 2019 | 53.62 Billion EUR | 2.4% |
| 2018 | 52.37 Billion EUR | 25.99% |
| 2017 | 41.56 Billion EUR | -11.46% |
| 2016 | 46.94 Billion EUR | 6.43% |
| 2015 | 44.11 Billion EUR | 7.26% |
| 2014 | 41.12 Billion EUR | 5.31% |
| 2013 | 39.05 Billion EUR | -9.05% |
| 2012 | 42.93 Billion EUR | -1.92% |
| 2011 | 43.77 Billion EUR | 36.9% |
| 2010 | 31.97 Billion EUR | 1.18% |
| 2009 | 31.6 Billion EUR | 17.41% |
| 2008 | 26.91 Billion EUR | -1.18% |
| 2007 | 27.23 Billion EUR | -14.73% |
| 2006 | 31.94 Billion EUR | -19.74% |
| 2005 | 39.8 Billion EUR | -2.39% |
| 2004 | 40.77 Billion EUR | 1098.7% |
| 2003 | 3.4 Billion EUR | -0.24% |
| 2002 | 3.4 Billion EUR | -18.39% |
| 2001 | 4.17 Billion EUR | 18.93% |
| 2000 | 3.51 Billion EUR | 9.78% |
| 1999 | 3.2 Billion EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 56.75 Billion EUR | 0.0% |
| 2024 Q1 | - EUR | -100.0% |
| 2023 Q3 | - EUR | -100.0% |
| 2023 Q1 | - EUR | -100.0% |
| 2023 Q2 | 52.4 Billion EUR | 0.0% |
| 2023 Q4 | 52.11 Billion EUR | 0.0% |
| 2023 FY | 52.11 Billion EUR | 2.03% |
| 2022 Q4 | 51.07 Billion EUR | 0.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 FY | 51.07 Billion EUR | -0.27% |
| 2022 Q3 | - EUR | -100.0% |
| 2022 Q2 | 50.52 Billion EUR | 0.0% |
| 2021 Q1 | - EUR | -100.0% |
| 2021 Q4 | 51.21 Billion EUR | 0.0% |
| 2021 Q2 | 48.95 Billion EUR | 0.0% |
| 2021 Q3 | - EUR | -100.0% |
| 2021 FY | 51.21 Billion EUR | -0.33% |
| 2020 Q1 | - EUR | -100.0% |
| 2020 Q4 | 51.38 Billion EUR | 0.0% |
| 2020 Q2 | 52.33 Billion EUR | 0.0% |
| 2020 FY | 51.38 Billion EUR | -4.19% |
| 2020 Q3 | - EUR | -100.0% |
| 2019 Q4 | 53.62 Billion EUR | 0.0% |
| 2019 Q3 | - EUR | -100.0% |
| 2019 Q2 | 54.02 Billion EUR | 0.0% |
| 2019 Q1 | - EUR | -100.0% |
| 2019 FY | 53.62 Billion EUR | 2.4% |
| 2018 Q3 | - EUR | -100.0% |
| 2018 Q1 | 53.41 Billion EUR | 28.49% |
| 2018 FY | 52.37 Billion EUR | 25.99% |
| 2018 Q4 | 52.37 Billion EUR | 0.0% |
| 2018 Q2 | 56.41 Billion EUR | 5.63% |
| 2017 FY | 41.56 Billion EUR | -11.46% |
| 2017 Q2 | 44.07 Billion EUR | 0.0% |
| 2017 Q3 | - EUR | -100.0% |
| 2017 Q4 | 41.56 Billion EUR | 0.0% |
| 2017 Q1 | - EUR | -100.0% |
| 2016 Q1 | - EUR | -100.0% |
| 2016 FY | 46.94 Billion EUR | 6.43% |
| 2016 Q4 | 46.94 Billion EUR | 0.0% |
| 2016 Q3 | - EUR | -100.0% |
| 2016 Q2 | 44.76 Billion EUR | 0.0% |
| 2015 Q1 | - EUR | -100.0% |
| 2015 FY | 44.11 Billion EUR | 7.26% |
| 2015 Q3 | - EUR | -100.0% |
| 2015 Q2 | 41.14 Billion EUR | 0.0% |
| 2015 Q4 | 44.11 Billion EUR | 0.0% |
| 2014 Q1 | - EUR | -100.0% |
| 2014 Q4 | 41.12 Billion EUR | 0.0% |
| 2014 Q2 | 38.95 Billion EUR | 0.0% |
| 2014 Q3 | - EUR | -100.0% |
| 2014 FY | 41.12 Billion EUR | 5.31% |
| 2013 Q3 | - EUR | -100.0% |
| 2013 Q4 | 39.05 Billion EUR | 0.0% |
| 2013 FY | 39.05 Billion EUR | -9.05% |
| 2013 Q1 | - EUR | -100.0% |
| 2013 Q2 | 40.79 Billion EUR | 0.0% |
| 2012 FY | 42.93 Billion EUR | -1.92% |
| 2012 Q4 | 42.93 Billion EUR | 0.0% |
| 2012 Q2 | 45.38 Billion EUR | 0.0% |
| 2011 Q4 | 43.77 Billion EUR | 0.0% |
| 2011 Q2 | 46.99 Billion EUR | 0.0% |
| 2011 FY | 43.77 Billion EUR | 36.9% |
| 2010 Q2 | 33.67 Billion EUR | 0.0% |
| 2010 Q4 | 31.97 Billion EUR | 0.0% |
| 2010 FY | 31.97 Billion EUR | 1.18% |
| 2009 Q4 | 31.6 Billion EUR | 0.0% |
| 2009 Q2 | 31.97 Billion EUR | 0.0% |
| 2009 FY | 31.6 Billion EUR | 17.41% |
| 2008 Q4 | 26.91 Billion EUR | 0.0% |
| 2008 FY | 26.91 Billion EUR | -1.18% |
| 2008 Q2 | 26.05 Billion EUR | 0.0% |
| 2007 Q4 | 27.23 Billion EUR | 0.0% |
| 2007 FY | 27.23 Billion EUR | -14.73% |
| 2007 Q2 | 28.96 Billion EUR | 0.0% |
| 2006 Q4 | 31.94 Billion EUR | 0.0% |
| 2006 Q2 | 36.42 Billion EUR | 0.0% |
| 2006 FY | 31.94 Billion EUR | -19.74% |
| 2005 Q4 | 39.8 Billion EUR | 0.0% |
| 2005 Q2 | 44.6 Billion EUR | 0.0% |
| 2005 FY | 39.8 Billion EUR | -2.39% |
| 2004 Q4 | 40.77 Billion EUR | 0.0% |
| 2004 FY | 40.77 Billion EUR | 1098.7% |
| 2004 Q2 | 3.7 Billion EUR | 0.0% |
| 2003 Q2 | 3.22 Billion EUR | 0.0% |
| 2003 FY | 3.4 Billion EUR | -0.24% |
| 2003 Q4 | 3.4 Billion EUR | 0.0% |
| 2002 FY | 3.4 Billion EUR | -18.39% |
| 2002 Q4 | 3.4 Billion EUR | 0.0% |
| 2002 Q2 | 3.51 Billion EUR | 0.0% |
| 2001 FY | 4.17 Billion EUR | 18.93% |
| 2000 FY | 3.51 Billion EUR | 9.78% |
| 1999 FY | 3.2 Billion EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| AstraZeneca PLC | 61.86 Billion USD | 15.767% |
| Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | 20.652% |
| CSPC Pharmaceutical Group Limited | 1.53 Billion USD | -3284.241% |
| Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | -76956.501% |
| Novartis AG | 53.19 Billion USD | 2.038% |
| PT Kalbe Farma Tbk. | 255.94 Million USD | -20260.592% |